GlobeNewswire by notified

Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany

Share
  • Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines
  • New penicillin production process will significantly improve ecological footprint and help secure European-based supply
  • Cutting-edge development hub will play key role in supporting long-term growth of leading biosimilar business

Basel, November 10, 2023 – Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.

The inauguration of a new facility for production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading development of biosimilars.

Sandoz has the only major remaining vertically-integrated production network for penicillins in Europe; penicillins are the leading category of antibiotics worldwide. The EUR 150 million Kundl investment, which includes a contribution of EUR 50 million from the Austrian federal government, represents a significant upgrade of penicillin API (active pharmaceutical ingredient) manufacturing.

Richard Saynor, CEO Sandoz said: "These investments strengthen our industrial presence in Europe, reinforce our commitment to environmental responsibility, and reaffirm our determination to be the world's leading and most valued generics and biosimilars company. Antibiotics are the backbone of modern medicine and the Kundl plant is a testament to the resilience of European manufacturing. The new development center in Holzkirchen will become a global hub for biosimilar expertise."

The EUR 25 million Holzkirchen investment will pave the way for the German site to become the leading Sandoz analytical characterization center for biosimilars.

The Austrian federal and Bavarian state governments have been highly supportive of these projects, recognizing their importance for ensuring availability of medicines and advancing medical research in Europe.

Disclaimer
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.

About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 22,000 people of more than 100 nationalities work together to bring Sandoz medicines to some 500 million patients worldwide, generating substantial global healthcare savings and an even larger total social impact. Its leading portfolio of more than 1500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to the year 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the first biosimilar in 2006. In 2022, Sandoz achieved sales of USD 9.1 billion and core EBITDA of USD 1.9 billion.

CONTACTS

Global Media Relations contactsInvestor Relations contacts
Global.MediaRelations@sandoz.comInvestor.Relations@sandoz.com
Joerg E. Allgaeuer
+49 171 838 4838
Karen M. King
+1 609 722 0982
Chris Lewis
+49 174 244 9501
Laurent de Weck
+41 61 529 14 85

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: Agenda special general meeting 29.03.202428.2.2024 08:00:00 CET | Press release

Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the agenda for the special general meeting of 29 March 2024. Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de agenda voor de bijzondere algemene vergadering van 29 maart 2024. Chère Madame, Cher Monsieur, Veuillez trouver ci-dessous les liens vers le récent communiqué de presse d’Intervest Offices & Warehouses concernant l’ordre du jour de l’assemblée générale spéciale du 29 mars 2024. Attachments ENG_Persbericht oproeping_FinNL_Persbericht oproeping_FinFR_Persbericht oproeping_Fin

GOGL – Fourth Quarter 2023 Results28.2.2024 08:00:00 CET | Press release

Golden Ocean Group Limited (NASDAQ/OSE: GOGL) (the “Company” or “Golden Ocean”), the world's largest listed owner of large size dry bulk vessels, today announced its unaudited results for the three and twelve months ended December 31, 2023. Highlights Net income of $57.5 million and earnings per share of $0.29 (basic) for the fourth quarter of 2023, compared with net income of $28.7 million and earnings per share of $0.14 (basic) for the third quarter of 2023.Net income of $112.3 million and earnings per share of $0.56 (basic) for full year 2023, compared with net income of $461.8 million and earnings per share of $2.30 (basic) for full year 2022.Adjusted EBITDA of $123.2 million for the fourth quarter of 2023, compared with $78.9 million for the third quarter of 2023.Adjusted net income of $64.6 million for the fourth quarter of 2023, compared to $22.0 million for the third quarter of 2023.Reported TCE rates for Capesize and Panamax vessels of $25,176 per day and $16,738 per day, resp

Mintos officially debuts in Italy and Spain, offering a new investment platform that makes investing easy and free of charge28.2.2024 08:00:00 CET | Press release

BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Following its official debut in the German market, Mintos, the multi-asset platform offering a unique mix of alternative and traditional investment options, continues its European rollout by making its official debut in the Italian and Spanish investment markets, with plans to expand to more countries in the near future. Since its founding in 2015, the platform has attracted over 500,000 users across Europe. Authorised by MiFID, the company currently manages over 600 million euros in assets under administration. Revealing insights into financial habits in Italy and Spain Mintos, in partnership with London-based research company Censuswide, unveils interesting insights into how Italians and Spaniards manage their finances. The survey, carried out on a sample of 4,000 investors based in different cities and regions of Italy and Spain, exposes a noteworthy trend – half of respondents from both countries are currently not actively investing in fina

Volta Finance Limited - Management Fee and Performance Fee Changes28.2.2024 08:00:00 CET | Press release

Volta Finance Limited (VTA / VTAS) Management Fee and Performance Fee changes NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 28 February 2024 The Board of Directors today announces that Volta Finance Limited (the “Company” or “Volta”) has agreed an alteration of the fee structure with its Investment Manager, AXA Investment Managers Paris (“AXA IMP” or the “Investment Manager”) under an amended and restated investment management agreement (“IMA”) dated on or around 28 February 2024 with effect from 31 March 2024. The Board is delighted to have reached agreement with AXA IMP on lowering the threshold of the tiered management fee and enhancing the annual performance fee structure. The management fee amendment will bring an immediate benefit to shareholders and will see a notable reduction should the Company grow. The revised performance fee arrangement will continue to provide an alignment of shareholders’ interests along with

Nexstim Receives NBS System 5 Order from Neurosurgery Customer in Germany28.2.2024 08:00:00 CET | Press release

Press release, Helsinki, 28 February 2024 at 9 AM (EET) Nexstim Receives NBS System 5 Order from Neurosurgery Customer in Germany Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from an existing customer. The system will be used in neurosurgery. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. The system provides information that may be used in the assessment of the primary motor cortex for pre-procedural planning. Mikko Karvinen, CEO of Nexstim, comments: “We are proud to have a unique product that is reputable among neurosurgical professionals: the NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain. I would like to thank our sales and marketing department for their persistent efforts towards both maintaining our current customer relationships as

HiddenA line styled icon from Orion Icon Library.Eye